BEAM
Price
$23.98
Change
-$0.39 (-1.60%)
Updated
Sep 11, 04:59 PM (EDT)
Capitalization
2.52B
59 days until earnings call
Intraday BUY SELL Signals
NTLA
Price
$11.77
Change
-$0.16 (-1.34%)
Updated
Sep 11, 04:06 PM (EDT)
Capitalization
1.67B
55 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs NTLA

BEAM vs NTLA Comparison Chart in %
View a ticker or compare two or three
VS
BEAM vs. NTLA commentary
Sep 11, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a StrongBuy and NTLA is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.52B) has a higher market cap than NTLA($1.67B). NTLA YTD gains are higher at: 32.703 vs. BEAM (-12.085). BEAM has higher annual earnings (EBITDA): -355.78M vs. NTLA (-408.24M). BEAM has more cash in the bank: 1.15B vs. NTLA (438M). NTLA has less debt than BEAM: NTLA (73.4M) vs BEAM (247M). BEAM has higher revenues than NTLA: BEAM (156M) vs NTLA (59.5M).
BEAMNTLABEAM / NTLA
Capitalization2.52B1.67B151%
EBITDA-355.78M-408.24M87%
Gain YTD-12.08532.703-37%
P/E RatioN/AN/A-
Revenue156M59.5M262%
Total Cash1.15B438M263%
Total Debt247M73.4M337%
FUNDAMENTALS RATINGS
BEAM vs NTLA: Fundamental Ratings
BEAM
NTLA
OUTLOOK RATING
1..100
764
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
25
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9298
PRICE GROWTH RATING
1..100
6056
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BEAM's Valuation (24) in the null industry is in the same range as NTLA (25) in the Biotechnology industry. This means that BEAM’s stock grew similarly to NTLA’s over the last 12 months.

BEAM's Profit vs Risk Rating (100) in the null industry is in the same range as NTLA (100) in the Biotechnology industry. This means that BEAM’s stock grew similarly to NTLA’s over the last 12 months.

BEAM's SMR Rating (92) in the null industry is in the same range as NTLA (98) in the Biotechnology industry. This means that BEAM’s stock grew similarly to NTLA’s over the last 12 months.

NTLA's Price Growth Rating (56) in the Biotechnology industry is in the same range as BEAM (60) in the null industry. This means that NTLA’s stock grew similarly to BEAM’s over the last 12 months.

NTLA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as BEAM (100) in the null industry. This means that NTLA’s stock grew similarly to BEAM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BEAMNTLA
RSI
ODDS (%)
Bullish Trend 2 days ago
80%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 8 days ago
76%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
76%
COMPARISON
Comparison
Sep 11, 2026
Stock price -- (BEAM: $24.37 vs. NTLA: $11.93)
Brand notoriety: BEAM and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 96% vs. NTLA: 108%
Market capitalization -- BEAM: $2.52B vs. NTLA: $1.67B
BEAM [@Biotechnology] is valued at $2.52B. NTLA’s [@Biotechnology] market capitalization is $1.67B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.42B. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green while NTLA’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, both BEAM and NTLA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 5 TA indicator(s) are bullish while NTLA’s TA Score has 3 bullish TA indicator(s).

  • BEAM’s TA Score: 5 bullish, 5 bearish.
  • NTLA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than NTLA.

Price Growth

BEAM (@Biotechnology) experienced а -17.28% price change this week, while NTLA (@Biotechnology) price change was -5.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.86%. For the same industry, the average monthly price growth was +6.57%, and the average quarterly price growth was +2531.02%.

Reported Earning Dates

BEAM is expected to report earnings on Nov 09, 2026.

NTLA is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-5.86% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
BEAM
Daily Signal:
Gain/Loss:
NTLA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JULM34.87-0.09
-0.25%
FT Vest U.S. Eq Max Buffr ETF - Jul
BAMV37.38-0.15
-0.41%
Brookstone Value Stock ETF
BASV30.81-0.33
-1.06%
Brown Advisory Sustainable Value ETF
IDEQ35.55-0.43
-1.20%
Lazard Active ETF TR
DFEV42.81-0.82
-1.88%
Dimensional Emerging Markets Value ETF